Proteon Therapeutics Announces Third Quarter 2019 Financial Results
October 31, 2019 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel,...
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
September 23, 2019 16:20 ET
|
Proteon Therapeutics, Inc.
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare...
Proteon Therapeutics Announces Second Quarter 2019 Financial Results
August 07, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to...
Proteon Therapeutics Announces First Quarter 2019 Financial Results
May 08, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Review of Potential Strategic Transactions
April 15, 2019 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
March 28, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
March 13, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
March 04, 2019 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
January 24, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
November 08, 2018 07:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...